drugset / Trial / NCT00427635

Efficacy and Safety of Esomeprazole Once Daily for the Treatment of GERD in Neonatal Patients

NCT00427635

Phase 3 Completed 32 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the difference between esomeprazole and placebo in the treatment of signs and symptoms as observed by 8-hour video and cardiorespiratory monitoring in neonatal patients.

Timeline

Start
2006-10
Primary completion
Completion
2009-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Esomeprazole Small molecule 0.5 mg/kg